Show simple item record

dc.contributor.authorYANARDAĞ, REFİYE
dc.contributor.authorCelik, Cagri
dc.contributor.authorBAYRAK, BERTAN BORAN
dc.contributor.authorHacihasanoglu Cakmak, Neziha
dc.date.accessioned2022-02-18T09:33:15Z
dc.date.available2022-02-18T09:33:15Z
dc.date.issued2022
dc.identifier.citationCelik C., BAYRAK B. B. , Hacihasanoglu Cakmak N., YANARDAĞ R., "Protective effect of edaravone on rat testis after valproic acid treatment", JOURNAL OF RESEARCH IN PHARMACY, cilt.26, sa.1, ss.52-62, 2022
dc.identifier.othervv_1032021
dc.identifier.otherav_452f921d-6820-483a-91d5-04314aa963d0
dc.identifier.urihttp://hdl.handle.net/20.500.12627/177428
dc.identifier.urihttps://doi.org/10.29228/jrp.103
dc.description.abstractValproic acid n-dipropyl-acetic acid, VPA) is a medication used as anticonvulsant in the treatment of bipolar disorder, and for migraine prophylaxis. Long-term use of VPA is known to trigger reproductive impairment, which is mediated by elevation of testicular oxidative stress. Edaravone is used in the treatment of cerebrovascular diseases. It can diffuse into many disease-affected organs, thus shows protective effects in numerous tissues including the heart, lung, and testis. The main goal of the present study was to determine the possible protective role of edaravone against VPA-induced oxidative testicular injury. Male Sprague Dawley rats were assigned into four groups. Control rats; rats given only edaravone (30 mg/kg/day); rats given only VPA (500 mg/kg/day); rats given VPA+edaravone for seven days. Edaravone and VPA were applied intraperitoneally. After eight days, testicular tissues were taken from rats. There was a statistically significant increase in the levels of reduced glutathione, lipid peroxidation, reactive oxygen species, total oxidant status, oxidative stress index, and DNA contents as well as catalase, superoxide dismutase, glutathione-related enzymes, gamma-glutamyl transferase, acid and alkaline phosphatases, lactate dehydrogenase, myeloperoxidase and sorbitol dehydrogenase activities in VPA group. More so, advanced oxidized protein products, protein carbonyl, and nitric oxide levels were also significantly increased in VPA group. Activities of glucose-6-phosphate dehydrogenase and sodium/potassium ATPase and total antioxidant status levels remarkably decreased in VPA given group. Treatment with edaravone to VPA group significantly reverted these alterations. These findings demonstrate that administration of edaravone has a beneficial effect against testicular injury in VPA-induced oxidative stress.
dc.language.isoeng
dc.subjectPharmacology (medical)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.titleProtective effect of edaravone on rat testis after valproic acid treatment
dc.typeMakale
dc.relation.journalJOURNAL OF RESEARCH IN PHARMACY
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , ,
dc.identifier.volume26
dc.identifier.issue1
dc.identifier.startpage52
dc.identifier.endpage62
dc.contributor.firstauthorID3060648


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record